Report
Valens Research

HUM - Embedded Expectations Analysis - 2018 10 24

Humana Inc. (HUM:USA) currently trades above recent averages relative to
UAFRS-based (Uniform) Earnings, with a 24.7x Uniform P/E. However, even at these levels, the market has bearish expectations for the firm, and management has concerns about their recent mergers, lower inpatient rates, and their ability to meet guidance

Specifically, management may lack confidence in the sustainability of their improved medical ratio, and may have concerns about the potential of their Kindred at Home and Curo Health Services acquisitions. Moreover, they may lack confidence in their ability to sustain robust performance in FY 2019, and may be exaggerating their excitement about the future of the company. Furthermore, they may lack confidence in their ability to drive meaningful EPS growth, and to drive value for their customers and shareholders. They may also lack confidence in their ability to find acquisition targets in FY 2019, and to sustain their inpatient admissions rates
Underlying
Humana Inc.

Humana is a holding company. Through its subsidiaries, the company is a health and well-being company. The company manages its business with three segments: Retail, which consists of products sold on a retail basis to individuals including medical and supplemental benefit plans, such as Medicare and state-based Medicaid Contracts; Group and Specialty, which consists of employer group commercial fully-insured medical and specialty health insurance benefits, including dental, vision and life insurance benefits, as well as administrative services only; and Healthcare Services, which includes pharmacy solutions, provider services, clinical care services, and predictive modeling and informatics services

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch